首页> 外国专利> Mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and structural templates

Mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and structural templates

机译:基于机理的转甲状腺素蛋白淀粉样变性抑制剂:联苯醚和结构模板的研究

摘要

Transthyretin (TTR), a tetrameric thyroxine (T4) carrier protein, is associated with a variety of amyloid diseases. Derivative of biphenyl ethers (BPE), which are shown to interact with a high affinity to its T4 binding site thereby preventing its aggregation and fibrillogenesis. They prevent fibrillogenesis by stabilizing the tetrameric ground state of transthyretin. Two compounds (2-(5-mercapto-[1,3,4]oxadiazol-2-yl)-phenol and 2,3,6-trichloro-N-(4H-[1,2,4]triazol-3-yl) exhibit the ability to arrest TTR amyloidosis. The dissociation constants for the binding of BPEs and compound 11 and 12 to TTR correlate with their efficacies of inhibiting amyloidosis. They also have the ability to inhibit the elongation of intermediate fibrils as well as show nearly complete (90%) disruption of the preformed fibrils. Biphenyl ethers and compounds 11 and 12 as very potent inhibitors of TTR fibrillization and inducible cytotoxicity.
机译:运甲状腺素蛋白(TTR)是一种四聚体甲状腺素(T4)载体蛋白,与多种淀粉样疾病有关。联苯醚(BPE)的衍生物,显示出与其T4结合位点具有高亲和力,从而阻止了其聚集和原纤维形成。它们通过稳定运甲状腺素蛋白的四聚体基态来防止原纤维形成。两种化合物(2-(5-巯基-[[1,3,4]恶二唑-2-基)-苯酚和2,3,6-三氯-N-(4H- [1,2,4]三唑-3- yl)具有阻止TTR淀粉样变性的能力,BPE和化合物11和12与TTR结合的解离常数与其抑制淀粉样变性的功效有关,还具有抑制中间原纤维伸长的能力,并且几乎可以显示完全(> 90%)破坏了预形成的原纤维联苯醚和化合物11和12是非常有效的TTR原纤维化和可诱导的细胞毒性抑制剂。

著录项

  • 公开/公告号US2010190832A1

    专利类型

  • 公开/公告日2010-07-29

    原文格式PDF

  • 申请/专利权人 AVADHESHA SUROLIA;

    申请/专利号US20090587990

  • 发明设计人 AVADHESHA SUROLIA;

    申请日2009-10-15

  • 分类号A61K31/09;A61K31/192;A61K31/11;A61K31/4245;A61K31/4196;A61K31/198;A61P25/28;A61P3;A61P25;

  • 国家 US

  • 入库时间 2022-08-21 18:53:17

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号